Opinion
Video
Author(s):
Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.
Secukinumab Demonstrates Long-Term Safety and Efficacy in Pediatric Patients with GPP
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
Thinking Outside the Psoriatic Box: Practical Points for Systemic Success
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
Fighting the Flare of GPP: Expert Insights on Spesolimab
Navigating Psoriasis Treatment Across Patient Populations